Literature DB >> 17553819

Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria.

Junji Yamamoto1, Tomoo Kosuge, Akio Saiura, Yoshihiro Sakamoto, Kazuaki Shimada, Tsuyoshi Sano, Tadatoshi Takayama, Yasuhiko Sugawara, Toshiharu Yamaguchi, Norihiro Kokudo, Masatoshi Makuuchi.   

Abstract

BACKGROUND: The aim of this study was to determine the long-term post-resection outcomes for cirrhotic patients with early-stage hepatocellular carcinoma (HCC).
METHODS: A total of 217 < or = 65-year-old cirrhotic patients who underwent hepatic resection were divided into four groups in accordance with the Milan criteria: Group 1, those who met the Milan criteria (n = 130); Group 2A, those with a solitary tumor > 5 cm in size (n = 12); Group 2B, those with 2 or 3 tumors > 3 cm in size (n = 35); and Group 2C, those with > or = 4 tumors (n = 33). Overall and recurrence-free survival were compared between the groups.
RESULTS: At 1, 3, 5 and 10 years, overall survival rates were 91, 67, 45 and 12%, and recurrence-free survival rates were 62, 26, 16 and 0%, respectively. Independent prognostic factors for overall survival were age, blood transfusion, tumor number, tumor size and microscopic vascular invasion; and for recurrence they were hepatitis C infection, tumor number, tumor size, microscopic vascular invasion and histological tumor grade. Group 1 patients had significantly better survival (5-year survival rate, 56%) than those of other groups (5-year survival rate, around 30%). The median tumor-free survival time was significantly shorter in Groups 2B and 2C (0.7 years and 0.6 years, respectively) than in Groups 1 and 2A.
CONCLUSIONS: Hepatic resection can confer a considerable overall survival benefit for cirrhotic patients with HCC who meet the Milan criteria. For patients with HCC who do not meet the criteria, however, hepatic resection has limited efficacy. We suggest that application of non-surgical therapy or expansion of the indications for liver transplantation may be warranted for such patient subsets.

Entities:  

Mesh:

Year:  2007        PMID: 17553819     DOI: 10.1093/jjco/hym025

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  18 in total

1.  Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria.

Authors:  Takanori Sakaguchi; Shohachi Suzuki; Yoshifumi Morita; Kousuke Oishi; Atsushi Suzuki; Kazuhiko Fukumoto; Keisuke Inaba; Satoshi Nakamura; Hiroyuki Konno
Journal:  Surg Today       Date:  2010-06-26       Impact factor: 2.549

2.  Microvascular infiltration has limited clinical value for treatment and prognosis in hepatocellular carcinoma.

Authors:  Nazario Portolani; Gian Luca Baiocchi; Sarah Molfino; Anna Benetti; Federico Gheza; Stefano Maria Giulini
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

3.  Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis.

Authors:  Hiroshi Wada; Hidetoshi Eguchi; Hiroaki Nagano; Shoji Kubo; Takuya Nakai; Masaki Kaibori; Michihiro Hayashi; Shigekazu Takemura; Shogo Tanaka; Yasuyuki Nakata; Kosuke Matsui; Morihiko Ishizaki; Fumitoshi Hirokawa; Koji Komeda; Kazuhisa Uchiyama; Masanori Kon; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2017-06-08       Impact factor: 2.549

4.  Diffusion-weighted imaging of hepatocellular carcinoma for predicting early recurrence and survival after hepatectomy.

Authors:  Ali Muhi; Tomoaki Ichikawa; Utaroh Motosugi; Katsuhiro Sano; Zareen Fatima; Masanori Matsuda; Hideki Fujii; Nobuyuki Enomoto; Tsutomu Araki
Journal:  Hepatol Int       Date:  2012-06-22       Impact factor: 6.047

5.  Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.

Authors:  Yongping Yang; Yinying Lu; Chunping Wang; Wenlin Bai; Jianhui Qu; Yan Chen; Xiujuan Chang; Linjing An; Lin Zhou; Zhen Zeng; Min Lou; Jiyun Lv
Journal:  Exp Ther Med       Date:  2011-12-01       Impact factor: 2.447

6.  Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma.

Authors:  Yasutaka Baba; Sadao Hayashi; Kazuto Ueno; Masayuki Nakajo; Shinichi Ueno; Fumitake Kubo; Yoshirou Baba; Masahiro Hamanoue; Susumu Hasegawa; Hirohito Tsubouchi; Yasuji Komorizono
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

7.  Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma.

Authors:  Mu-Xing Li; Hong Zhao; Xin-Yu Bi; Zhi-Yu Li; Zhen Huang; Yue Han; Jian-Guo Zhou; Jian-Jun Zhao; Ye-Fan Zhang; Wen-Qiang Wei; Dong-Bin Zhao; Jian-Qiang Cai
Journal:  Tumour Biol       Date:  2016-01-15

8.  Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection.

Authors:  Hiroaki Shiba; Yuichi Ishida; Shigeki Wakiyama; Tomonori Iida; Michinori Matsumoto; Taro Sakamoto; Ryusuke Ito; Takeshi Gocho; Kenei Furukawa; Yuki Fujiwara; Shoichi Hirohara; Takeyuki Misawa; Katsuhiko Yanaga
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

9.  Early Hepatocellular Carcinoma Treated by Radiofrequency Ablation-Mid- and Long-Term Outcomes.

Authors:  Amar Mukund; Prayas Vats; Ankur Jindal; Yashwant Patidar; Shiv K Sarin
Journal:  J Clin Exp Hepatol       Date:  2020-05-04

10.  Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma.

Authors:  Jae Hyun Yoon; Won Jae Lee; Sun Min Kim; Kwang Tack Kim; Sung Bum Cho; Hee Joon Kim; Yang Seok Ko; Hyun Yi Kook; Chung Hwan Jun; Sung Kyu Choi; Ban Seok Kim; Seo Yeon Cho; Hye-Su You; Yohan Lee; Seyeong Son
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.